ALDEYRA THERAPEUTICS INC's ticker is ALDX and the CUSIP is 01438T106. A total of 97 filers reported holding ALDEYRA THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.36 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $292 | -30.5% | 43,723 | -12.6% | 0.01% | -22.2% |
| Q2 2023 | $420 | -28.3% | 50,000 | -15.2% | 0.01% | -35.7% |
| Q1 2023 | $586 | +15.1% | 58,968 | -19.4% | 0.01% | 0.0% |
| Q4 2022 | $509 | -99.9% | 73,196 | -5.8% | 0.01% | +27.3% |
| Q3 2022 | $415,000 | +29.7% | 77,692 | -3.2% | 0.01% | +10.0% |
| Q2 2022 | $320,000 | -44.6% | 80,235 | -38.3% | 0.01% | -23.1% |
| Q1 2022 | $578,000 | +13.3% | 130,000 | +2.0% | 0.01% | +8.3% |
| Q4 2021 | $510,000 | -60.6% | 127,447 | -13.6% | 0.01% | -57.1% |
| Q3 2021 | $1,295,000 | -18.9% | 147,439 | +4.6% | 0.03% | -20.0% |
| Q2 2021 | $1,596,000 | -11.4% | 140,904 | -7.1% | 0.04% | -12.5% |
| Q1 2021 | $1,802,000 | +133.7% | 151,683 | +34.9% | 0.04% | +166.7% |
| Q4 2020 | $771,000 | -11.1% | 112,452 | -3.9% | 0.02% | -34.8% |
| Q3 2020 | $867,000 | +79.9% | 116,995 | +1.1% | 0.02% | +64.3% |
| Q2 2020 | $482,000 | +32.4% | 115,694 | -21.4% | 0.01% | 0.0% |
| Q1 2020 | $364,000 | -68.7% | 147,257 | -26.4% | 0.01% | -26.3% |
| Q4 2019 | $1,162,000 | +10.2% | 200,000 | 0.0% | 0.02% | -9.5% |
| Q3 2019 | $1,054,000 | -12.2% | 200,000 | 0.0% | 0.02% | -34.4% |
| Q2 2019 | $1,200,000 | -33.6% | 200,000 | 0.0% | 0.03% | -28.9% |
| Q1 2019 | $1,806,000 | +17.6% | 200,000 | +8.1% | 0.04% | -29.7% |
| Q4 2018 | $1,536,000 | -39.8% | 185,000 | 0.0% | 0.06% | -4.5% |
| Q3 2018 | $2,553,000 | +697.8% | 185,000 | +360.2% | 0.07% | +737.5% |
| Q2 2018 | $320,000 | -10.1% | 40,200 | -15.2% | 0.01% | -27.3% |
| Q1 2018 | $356,000 | +4.7% | 47,400 | -5.2% | 0.01% | +22.2% |
| Q4 2017 | $340,000 | -5.6% | 50,000 | 0.0% | 0.01% | -30.8% |
| Q3 2017 | $360,000 | +25.0% | 50,000 | -19.4% | 0.01% | +8.3% |
| Q2 2017 | $288,000 | -11.4% | 62,000 | -4.6% | 0.01% | -7.7% |
| Q1 2017 | $325,000 | -6.6% | 65,000 | 0.0% | 0.01% | -23.5% |
| Q4 2016 | $348,000 | -31.5% | 65,000 | 0.0% | 0.02% | -45.2% |
| Q3 2016 | $508,000 | +36.2% | 65,000 | -0.9% | 0.03% | +6.9% |
| Q2 2016 | $373,000 | +25.2% | 65,610 | -7.8% | 0.03% | +123.1% |
| Q1 2016 | $298,000 | -42.1% | 71,172 | -6.4% | 0.01% | -62.9% |
| Q4 2015 | $515,000 | +16.3% | 76,000 | 0.0% | 0.04% | +75.0% |
| Q3 2015 | $443,000 | +225.7% | 76,000 | +334.3% | 0.02% | +300.0% |
| Q2 2015 | $136,000 | – | 17,500 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 908,488 | $6,232,000 | 2.88% |
| Knoll Capital Management, LLC | 569,405 | $3,906,000 | 2.66% |
| Mesirow Financial Investment Management, Inc. | 64,698 | $443,828,000 | 1.40% |
| Ghost Tree Capital, LLC | 650,000 | $4,459,000 | 0.99% |
| Johnson & Johnson Innovation - JJDC, Inc. | 594,834 | $4,081,000 | 0.53% |
| Perceptive Advisors | 6,285,458 | $43,118,000 | 0.46% |
| Affinity Asset Advisors, LLC | 100,000 | $686,000 | 0.36% |
| ACUTA CAPITAL PARTNERS, LLC | 192,500 | $1,321,000 | 0.36% |
| Avidity Partners Management LP | 1,435,000 | $9,844,000 | 0.32% |
| APOGEM CAPITAL LLC | 55,821 | $383,000 | 0.26% |